Remdesivir was generally well tolerated and the most common adverse events were not serious in about 20% of patients: nausea, headache and constipation; the most common laboratory abnormalities were hypokalemia, anemia and thrombocytopenia; in only four patients, remdesivir was discontinued because of a significantly elevated alanine aminotransferase level. This evidence concerns the gene GPT and anemia.